PortfoliosLab logo
Atai Life Sciences N.V. (9VC.DE)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

NL0015000DX5

Highlights

Market Cap

€269.89M

EPS (TTM)

-€0.82

Total Revenue (TTM)

€308.00K

Year Range

€0.93 - €2.50

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of €10,000 in Atai Life Sciences N.V., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%NovemberDecember2025FebruaryMarchApril
-87.71%
17.48%
9VC.DE (Atai Life Sciences N.V.)
Benchmark (^GSPC)

Returns By Period

Atai Life Sciences N.V. had a return of 7.61% year-to-date (YTD) and -23.87% in the last 12 months.


9VC.DE

YTD

7.61%

1M

-2.48%

6M

23.87%

1Y

-23.87%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-6.06%

1M

-2.95%

6M

-4.87%

1Y

8.34%

5Y*

13.98%

10Y*

10.15%

*Annualized

Monthly Returns

The table below presents the monthly returns of 9VC.DE, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202522.33%9.60%-14.28%-6.37%7.61%
202423.38%12.02%-5.01%0.52%-20.94%-11.20%11.14%-17.31%-9.92%-11.01%75.79%-26.49%-11.80%
2023-29.98%-3.94%-0.00%11.73%-5.05%-12.05%27.44%-22.72%-13.98%-19.21%1.70%36.75%-40.26%
2022-27.78%6.41%-7.23%4.83%0.00%-27.52%13.39%9.55%-22.02%-8.32%4.43%-28.73%-64.20%
2021-4.67%-36.47%-39.44%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of 9VC.DE is 47, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of 9VC.DE is 4747
Overall Rank
The Sharpe Ratio Rank of 9VC.DE is 4444
Sharpe Ratio Rank
The Sortino Ratio Rank of 9VC.DE is 5151
Sortino Ratio Rank
The Omega Ratio Rank of 9VC.DE is 4949
Omega Ratio Rank
The Calmar Ratio Rank of 9VC.DE is 4444
Calmar Ratio Rank
The Martin Ratio Rank of 9VC.DE is 4646
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Atai Life Sciences N.V. (9VC.DE) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The chart of Sharpe ratio for 9VC.DE, currently valued at -0.14, compared to the broader market-2.00-1.000.001.002.003.00
9VC.DE: -0.14
^GSPC: 0.46
The chart of Sortino ratio for 9VC.DE, currently valued at 0.45, compared to the broader market-6.00-4.00-2.000.002.004.00
9VC.DE: 0.45
^GSPC: 0.77
The chart of Omega ratio for 9VC.DE, currently valued at 1.05, compared to the broader market0.501.001.502.00
9VC.DE: 1.05
^GSPC: 1.11
The chart of Calmar ratio for 9VC.DE, currently valued at -0.14, compared to the broader market0.001.002.003.004.005.00
9VC.DE: -0.14
^GSPC: 0.47
The chart of Martin ratio for 9VC.DE, currently valued at -0.31, compared to the broader market-5.000.005.0010.0015.0020.00
9VC.DE: -0.31
^GSPC: 1.94

The current Atai Life Sciences N.V. Sharpe ratio is -0.14. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Atai Life Sciences N.V. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2025FebruaryMarchApril
-0.14
0.12
9VC.DE (Atai Life Sciences N.V.)
Benchmark (^GSPC)

Dividends

Dividend History


Atai Life Sciences N.V. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2025FebruaryMarchApril
-87.71%
-17.54%
9VC.DE (Atai Life Sciences N.V.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Atai Life Sciences N.V.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Atai Life Sciences N.V. was 91.16%, occurring on Oct 31, 2024. The portfolio has not yet recovered.

The current Atai Life Sciences N.V. drawdown is 87.71%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-91.16%Nov 19, 2021741Oct 31, 2024

Volatility

Volatility Chart

The current Atai Life Sciences N.V. volatility is 25.96%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%NovemberDecember2025FebruaryMarchApril
25.96%
15.98%
9VC.DE (Atai Life Sciences N.V.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Atai Life Sciences N.V. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items